G1 THERAPEUTICS INC (GTHX) Forecast, Price Target & Analyst Ratings
NASDAQ:GTHX • US3621LQ1099
7.15 USD
0 (0%)
At close: Sep 17, 2024
7.14 USD
-0.01 (-0.14%)
After Hours: 9/17/2024, 8:10:49 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for G1 THERAPEUTICS INC (GTHX).
Forecast Snapshot
Consensus Price Target
$7.29
+ 2.00% Upside
Next Earnings Forecast
Release DateOct 30, 2024
PeriodQ3 / 2024
EPS Estimate-$0.10
Revenue Estimate18.404M
ChartMill Buy Consensus
74.55%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$7.29
Upside
+ 2.00%
From current price of $7.15 to mean target of $7.29, Based on 11 analyst forecasts
Low
$7.22
Median
$7.29
High
$7.51
Price Target Revisions
1 Month
58.89%
3 Months
-15.88%
Price Target Summary
11 analysts have analysed GTHX and the average price target is 7.29 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 7.15.
The average price target has been revised downward by 15.88% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
74.55%
GTHX was analyzed by 11 analysts. The buy percentage consensus is at 75. So analysts seem to be have mildly positive about GTHX.
In the last month the buy percentage fell by 5 points. So the trust of analysts is decreasing.
GTHX was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-08-07 | Needham | Downgrade | Buy -> Hold |
| 2024-06-25 | Needham | Maintains | Buy -> Buy |
| 2024-06-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-06-13 | Needham | Reiterate | Buy -> Buy |
| 2024-05-28 | Needham | Reiterate | Buy -> Buy |
| 2024-05-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-22 | Needham | Reiterate | Buy -> Buy |
| 2024-05-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-01 | Needham | Reiterate | Buy -> Buy |
| 2024-04-12 | Needham | Reiterate | Buy -> Buy |
| 2024-02-28 | Needham | Reiterate | Buy -> Buy |
| 2024-02-13 | Needham | Maintains | Buy -> Buy |
| 2024-02-13 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-01-24 | Needham | Reiterate | Buy -> Buy |
| 2023-12-06 | Needham | Reiterate | Buy -> Buy |
| 2023-10-30 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-10-06 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2023-08-03 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-08-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-02 | EF Hutton | Reiterate | Buy |
| 2023-08-02 | Needham | Maintains | Buy -> Buy |
| 2023-06-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-05 | Needham | Reiterate | Buy -> Buy |
| 2023-06-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateOct 30, 2024
PeriodQ3 / 2024
EPS Estimate-$0.10
Revenue Estimate18.404M
Revenue Q2Q49.63%
EPS Q2Q70.13%
Number of Analysts7
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.20%
EPS (1 Month)
0.00%
EPS (3 Months)
24.07%
Next Earnings Summary
GTHX is expected to report earnings on 10/30/2024. The consensus EPS estimate for the next earnings is -0.1 USD and the consensus revenue estimate is 18.40M USD.
The next earnings revenue estimate has been revised upward by 0.2% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 31.48M -30.49% | 51.3M 62.96% | 82.511M 60.84% | 75.014M -9.09% | 96.383M 28.49% | 110.55M 14.70% | 135.7M 22.75% | 169.54M 24.94% | 217.21M 28.12% | 276.74M 27.41% | |
| EBITDA YoY % growth | -141.99M -48.06% | -135.65M 4.47% | -39.014M 71.24% | -25.607M 34.36% | -13.449M 47.48% | 493.41M 3,768.83% | 30.784M -93.76% | 48.124M 56.33% | 60.925M 26.60% | 66.484M 9.12% | |
| EBIT YoY % growth | -142.46M -47.66% | -136.18M 4.41% | -39.527M 70.97% | -25.141M 36.39% | -11.615M 53.80% | 190.15M 1,737.11% | 4.944M -97.40% | 28.275M 471.91% | 72.453M 156.24% | 116.92M 61.37% | |
| Operating Margin | -452.54% | -265.46% | -47.91% | -33.52% | -12.05% | 172.00% | 3.64% | 16.68% | 33.36% | 42.25% | |
| EPS YoY % growth | -3.53 -34.22% | -3.39 3.97% | -0.95 71.98% | -0.42 55.71% | 0.05 112.73% | 0.22 319.05% | 0.22 | 0.50 122.73% | 0.85 70.41% | 1.34 56.89% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.10 70.13% | -0.13 38.99% | -0.16 18.91% | -0.13 -25.46% | -0.09 13.66% | -0.05 57.40% | -0.11 32.70% | -0.10 19.51% | -0.08 9.60% | -0.07 -19.63% |
| Revenue Q2Q % growth | 18.404M 49.63% | 21.041M 41.47% | 19.136M 32.19% | 21.706M 31.19% | 24.305M 32.06% | 26.657M 26.69% | 18.006M -5.91% | 19.163M -11.72% | 20.341M -16.31% | 22.134M -16.97% |
| EBITDA Q2Q % growth | -3.871M 75.78% | -7.65M 9.10% | -2.04M 77.15% | -2.04M 38.07% | -2.04M 47.30% | -2.04M 73.33% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -4.39M 73.18% | -7.195M 19.41% | -7.987M 11.73% | -4.38M -23.90% | -1.793M 59.15% | 1.814M 125.21% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
30.77%
EPS Next 5 Year
20.36%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
10.30%
Revenue Next 5 Year
15.53%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
133.69%
EBIT Next 5 Year
24.98%
G1 THERAPEUTICS INC / GTHX Forecast FAQ
What do analysts expect the price target to be for G1 THERAPEUTICS INC (GTHX)?
11 analysts have analysed GTHX and the average price target is 7.29 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 7.15.
Can you provide the upcoming earnings date for G1 THERAPEUTICS INC?
G1 THERAPEUTICS INC (GTHX) will report earnings on 2024-10-30, after the market close.
What are the consensus estimates for G1 THERAPEUTICS INC (GTHX) next earnings?
The consensus EPS estimate for the next earnings of G1 THERAPEUTICS INC (GTHX) is -0.1 USD and the consensus revenue estimate is 18.40M USD.
How many analysts cover G1 THERAPEUTICS INC (GTHX) stock?
The number of analysts covering G1 THERAPEUTICS INC (GTHX) is 11.